BioSig Technologies (BSGM) Corporate Presentation from NobleCon18Research, News and Market Data on BioSig TechnologiesNobleCon 18 Complete Rebroadcast
|
Access to Exclusive Content. FREE for Registered Users Only.
Join the Channelchek Investor Community to access equity research, video content, events, and much more. All at no cost.


Welcome to the Channelchek Investor Community
We’ve updated the entire site to bring you faster navigation and increased content at every level. Channelchek is now North America’s leading platform for access to regulated and independent company sponsored equity research.
Don't have an account? Join
Forgot passwordBy clicking “Log In” you agree to Channelchek.com Terms of Use and acknowledge that Channelchek.com Privacy Policy applies to you.
Related News

10/6/2026
Health
Release – GeoVax to Highlight Next-Generation MVA Vaccine and Manufacturing Advances at World Vaccine Congress Europe 2026
GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies for infectious diseases and cancer, today announced that Senthil Ranganathan, PhD, Vice President, Technical Development and CMC...
6 min read

10/6/2026
Technology
Release – ISG Launches Marketing Advisory Practice to Turn Marketing Investment into Business Value
Information Services Group (ISG) (Nasdaq: III), a global AI-centered technology research and advisory firm, today announced the launch of ISG Marketing Advisory, a comprehensive suite of consulting, design and implementation...
4 min read

10/6/2026
Aerospace and Defense
Release – V2X to Showcase Advanced Technology Mission Solutions at AUSA Annual Meeting 2026
V2X, Inc. (NYSE: VVX) will showcase its advanced technology solutions designed to enhance protection, readiness, security, and battlefield connectivity at the 2026 Association of the United States Army (AUSA) Annual...
3 min read

10/6/2026
Health
Release – Ocugen Appoints Industry Executive Jolanda Crombach General Manager of European Affiliate
Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on developing and commercializing novel gene therapies to address blindness diseases, today announced the appointment of Jolanda Crombach,...
5 min read
Inbox Intel from Channelchek.
Informed investors make more money. And it’s all about timing. Get it when it happens.